Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Merck & Co Inc (NYSE:MRK)

65.13
Delayed Data
As of Sep 22
 -0.47 / -0.72%
Today’s Change
58.29
Today|||52-Week Range
66.80
+10.63%
Year-to-Date
US Market Indexes Mostly Higher
Sep 22 / GuruFocus News - Paid Partner Content
Oncology Space in Focus this Week on ESMO Presentations
Sep 15 / Zacks.com - Paid Partner Content
Gilead's (GILD) Epclusa Receives Label Expansion in Canada
Sep 22 / Zacks.com - Paid Partner Content
Bristol-Myers (BMY) Collaborates With Halozyme for ENHANZE
Sep 15 / Zacks.com - Paid Partner Content
Pfizer-Merck KGaA Skin Cancer Drug Bavencio Gets EU Approval
Sep 22 / Zacks.com - Paid Partner Content
Biosimilar 2017 Progress Report: Stocks in Focus
Sep 14 / Zacks.com - Paid Partner Content
Dow 30 Stock Roundup: BA Wins $600M Air Force Contract, JPM Invests in Bill.com
Sep 22 / Zacks.com - Paid Partner Content
Moderna Therapeutics raises hopes for drug after human trials
Sep 14 / FT.com - Paid Partner Content
Cancer Space Update: Mixed Week for Pfizer, Roche Falters
Sep 22 / Zacks.com - Paid Partner Content
Nektar (NKTR) Starts PROPEL Combo Study for Cancer Candidate
Sep 13 / Zacks.com - Paid Partner Content
Pfizer Sues J&J, Accuses it of Preventing Inflectra Uptake
Sep 21 / Zacks.com - Paid Partner Content
Bristol-Myers Reports Positive Results from Melanoma Study
Sep 12 / Zacks.com - Paid Partner Content
2 Important Dates for Big Pharma
Sep 20 / GuruFocus News - Paid Partner Content
AstraZeneca's Lung Cancer Study Data Promising, Shares Spike
Sep 11 / Zacks.com - Paid Partner Content
Roche (RHHBY) Announces Positive Data on Leukemia Drug
Sep 19 / Zacks.com - Paid Partner Content
Trump and jobs: the tweets and the facts
Aug 28 / FT.com - Paid Partner Content
Roche's (RHHBY) Tecentriq Studies Put on Partial Hold by FDA
Sep 18 / Zacks.com - Paid Partner Content